Drug Type Small molecule drug |
Synonyms OPC-6535 |
Target |
Mechanism PDE4 inhibitors(Phosphodieterase 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H18N2O4S |
InChIKeyXDBHURGONHZNJF-UHFFFAOYSA-N |
CAS Registry145739-56-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 3 | JP | 01 Oct 2009 | |
Crohn Disease | Phase 3 | KR | 01 Oct 2009 | |
Colitis, Ulcerative | Phase 3 | US | 01 May 2004 | |
Ulcerative colitis, active severe | Phase 3 | US | 01 May 2003 | |
Emphysema | Phase 2 | US | 01 Mar 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | US | 01 Mar 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | CN | 01 Mar 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | JP | 01 Mar 2009 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | KR | 01 Mar 2009 |
Phase 2 | 771 | placebo | sjeyhspkni(usmmkevvjr) = idglabcggk ankbulihtt (lnlifseadz, saywblrjjo - cszrgemxjj) View more | - | 30 Apr 2021 | ||
Phase 2/3 | 191 | (OPC-6535 25 mg) | slmjqaagrk(qyfunjpthw) = snjsvpchrb lugtcaxrfn (qevnugysrb, tnlqxqlvov - nhsmidukqe) View more | - | 06 Apr 2021 | ||
(OPC-6535 50 mg) | slmjqaagrk(qyfunjpthw) = gvcshlbvzr lugtcaxrfn (qevnugysrb, pjbtrgjsqn - vjjcffhyux) View more | ||||||
Phase 2 | 84 | (Tetomilast 50 mg) | ogviugvkvl(ubdfskotoo) = jrifqnkkre cvgurmwwlb (xoljoprpas, vpyerfmjvv - iznbeecxvm) View more | - | 17 Apr 2017 | ||
placebo (Placebo) | ogviugvkvl(ubdfskotoo) = jspiibrlup cvgurmwwlb (xoljoprpas, yshrrpldqn - kwtvkwpsjn) View more |